Androisoxazole

Androisoxazole (brand names Androxan, Neo-Ponden, Neo-Pondus), also known as 17α-methyl-5α-androstano[3,2-c]isoxazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) that is marketed in Spain and Italy.[1][2][3][4] It is closely related to stanozolol, differing only in having an isoxazole instead of pyrazole ring fused to the A ring,[4] and is also related to furazabol, prostanozol, and danazol.

Androisoxazole
Clinical data
Trade namesAndroxan, Neo-Ponden, Neo-Pondus
Other names17α-Methyl-5α-androstano[3,2-c]isoxazol-17β-ol
Routes of
administration
By mouth
Drug classAndrogen; Anabolic steroid
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H31NO2
Molar mass329.484 g·mol−1
3D model (JSmol)
  (verify)

References

  1. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1.
  2. Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 384–. ISBN 978-3-642-66353-6.
  3. ANTONINI FM, VERDI G (October 1961). "[Preliminary results of experience with a new anabolic steroid, "androisoxazole," in the aged.]". Minerva Medica (in Italian). 52: 3437–41. PMID 13861810.
  4. ARNOLD A, POTTS GO, BEYLER AL (December 1963). "Relative Oral Anabolic to Androgenic Activity Ratios of Androisoxazole, Ethylestrenol, Methylandrostenolisoxazole and Testosterone". Acta Endocrinologica. 44 (4): 490–8. doi:10.1530/acta.0.0440490. PMID 14082537.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.